Last reviewed · How we verify
C21
C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses.
C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses. Used for Advanced solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | C21 |
|---|---|
| Also known as | Buloxibutid, Compound 21, Compund 21, Buloxibutid, Compound 21 |
| Sponsor | Vicore Pharma AB |
| Drug class | CD40 agonist |
| Target | CD40 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD40 is a co-stimulatory molecule on antigen-presenting cells and B cells. Agonism of CD40 promotes T-cell activation, B-cell maturation, and dendritic cell function, leading to enhanced adaptive immunity against cancer. This mechanism is being explored in combination with checkpoint inhibitors and other immunotherapies.
Approved indications
- Advanced solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Cytokine release syndrome
- Infusion-related reactions
- Fatigue
- Fever
Key clinical trials
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. (PHASE2)
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) (PHASE1)
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (PHASE1, PHASE2)
- Spatial Hearing Perception in Bilateral Cochlear Implant Children (NA)
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (PHASE1, PHASE2)
- Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia (EARLY_PHASE1)
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (PHASE1, PHASE2)
- Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C21 CI brief — competitive landscape report
- C21 updates RSS · CI watch RSS
- Vicore Pharma AB portfolio CI